Overview

A Trial of Vitamin B12 in Septic Shock

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:
0

Participant gender:
All

Summary

This study will randomize 30 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to reduce vasopressor dose at 3 hours.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Hydroxocobalamin
Vitamin B 12
Vitamin B Complex
Vitamins

Criteria

Inclusion Criteria:

- Adult patients at least 18 years of age

- Admitted to the Medical Intensive Care Unit (MICU) service at Froedtert Hospital

Exclusion Criteria:

-